ZA OBOLJELE OD MIJELODISPLASTIČNOG SINDROMA DONOSIMO IPSS-R KALKULATOR RIZIKA

IPSS-R je međunarodni prognostički sistem bodovanja razvijen za mijelodisplastične sindrome. MDS Foundation najavljuje razvoj novog prognostičkog sustava bodovanja, IPSS-Molecular, koji će značajno poboljšati stratifikaciju rizika nakon postavljanja dijagnoze kako bismo bolje informirali o načinu na koji se izrađuju planovi liječenja za pacijente s mijelodisplastičnim sindromom.


Više od dva desetljeća, stratifikacija rizika pacijenata s MDS-om pri postavljanju dijagnoze temeljila se na dijagnostičkoj krvnoj slici, morfologiji i citogenetici putem Međunarodnog sustava prognostičkog bodovanja. Posljednjih godina otkriven je kompletan katalog gena mutiranih u MDS-u. 

Stvaranje učinkovitog skupa prognostičkih smjernica bilo je posebno važno za MDS jer su trenutni klinički tijekovi vrlo heterogeni. U ovom nedostatku ciljanih terapija, stratifikacija rizika pri postavljanju dijagnoze ključna je u donošenju odluka o liječenju.

U nastavku je izvorni tekst u kojemu možete svoje podatke unijeti u “kalkulator”, koji će izračunati Vaš rizik. Tekst je na engleskom jeziku.
 
Izvor: MDS Foundation

 

 

 
 
MOLECULAR INTERNATIONAL PROGNOSTIC SCORING SYSTEM DEVELOPED FOR MYELODYSPLASTIC SYNDROMES
EFFICIENT, ACCURATE RISK STRATIFICATION WILL TRANSFORM PATIENT CARE

We are thrilled to announce the development of a new prognostic scoring system, the IPSS-Molecular, that will significantly improve risk stratification upon diagnosis to better inform the way treatment plans are built for patients with Myelodysplastic Syndromes.

 

“By considering each patient’s genetic make up in the IPSS-M we can now truly deliver patient tailored risk stratification,” says Dr. Elli Papaemmanuil of the Memorial Sloan Kettering Cancer Center. “This will enable optimized treatment decisions tailored to those most in need of intervention, and sets a biological framework for the design of future clinical trials.” 

For more than two decades, MDS patient risk stratification at diagnosis was based on diagnostic blood counts, morphology, and cytogenetics through the International Prognostic Scoring System. In recent years, a complete catalog of the genes mutated in MDS has been discovered. However, even though patients increasingly receive panel gene testing at diagnosis, there were no guidelines as to how this information could be used clinically to guide risk stratification and treatment decisions.

The creation of an effective set of prognostic guidelines was especially important for MDS because current clinical courses are very heterogeneous. In this absence of targeted therapies, risk stratification at diagnosis is critical in guiding treatment decisions.

EXPLORE THE CALCULATOR
View the official Press Release here.
 
Twitter
Facebook
Instagram
 

MDS Foundation Headquarters

4573 South Broad Street, Suite 150, Yardville, NJ 08620
Within the US: 1-800-637-0839, Outside the US: 1-609-298-1035, Fax: 1-609-298-0590

http://www.mds-foundation.org 

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.

 

Podijeli

Zagreb, HR
4°C
sumaglica

Hrvatska udruga leukemija i limfomi
predsjednik Dražen Vincek
Trg hrvatskih velikana 2/ll
10 000 Zagreb
OIB:51774844072
MB: 01136763
REG. BR.: 00000797
GSM: +385 (0)91 4873 561
TEL: +385 (0)1 4873 561
e-mail: udruga.hull.zagreb@gmail.com
Web adresa: www.hull.hr
IBAN: HR 36 2340 0091 1100 4711 4
SWIFT CODE: PBZGHR2X

Važni datumi

studeni 2022

NedPonUtoSriČetPetSub

1

Mjesec borbe prot...

2


3


4


5


6


7


8


9


10


11


12


13


14

Svjetski dan šeće...

15


16


17


18


19


20


21


22


23


24


25


26


27


28


29


30


Health through Knowledge

Klasa optimist

Igor Delač- Samo zbog vas

(Ivan Zečić/Miroslav Zečić – Miroslav Zečić/Ivan Zečić) ℗ 2021 Croatia Records

Istaknuti sponzori HULL-a